Edgewise Therapeutics

A Movement in Muscle

Search for:
Clinical Trials
Careers
Investors & News
Menu
Disease Areas

Muscular Dystrophy

Hypertrophic Cardiomyopathy

Learn more about how our science is driving a new understanding of muscle and its potential to transform human health.
Explore Muscle

Science & Pipeline

Pipeline

Sevasemten

EDG-7500

Clinical Trials

Posters & Presentations

All of us at Edgewise are committed to developing new medicines for people facing serious muscle diseases with unmet medical needs.
Explore our Science

Patients & Families

Support for Becker

Support for Duchenne

Support for HCM

Patient Stories

We honor the experience of individuals and families living with and facing the challenges of serious muscle disease.
Read their Stories

Company

Leadership Team

Careers

Contact Us

Our vision is to improve the lives of patients and families suffering from serious muscle diseases by building the world’s leading muscle-focused company.
Learn More

Corporate Profile

News

Events & Presentations

Analyst Coverage

Stock Info

Stock Quote

Stock Chart

Historical Stock Quote

Investment Calculator

Financials

Quarterly Results

SEC Filings

Governance

Governance Documents

Committee Composition

Resources

Investor FAQs

Investor Email Alerts

Investor Contacts

Posters & Presentations

Scientific Posters and Presentations

Use the search tool to explore downloadable articles, posters, presentations, video symposia, news releases, and investor resources and take a deep dive into our leadership in serious muscle disease.

Muscular Dystrophy

April 2024

American Academy of Neurology 2024 Annual Meeting

Effects of Sevasemten (EDG-5506), a Fast Myosin Modulator, on Function and Biomarkers of Muscle Damage in Adults with Becker Muscular Dystrophy

View Presentation

Muscular Dystrophy

March 2024

2024 MDA Annual Clinical and Scientific Conference Industry Forum

Protecting and preserving dystrophic muscle: The balance between exercise and contraction-induced muscle injury

View Presentation

Muscular Dystrophy

March 2024

2024 MDA Annual Clinical and Scientific Conference

North Star (NSAA and NSAD) Functional Assessments in Individuals with Becker Muscular Dystrophy

Muscular Dystrophy

March 2024

2024 MDA Annual Clinical and Scientific Conference

Functional and Muscle Damage Biomarker Changes Following Treatment with EDG-5506, a Fast Myosin Modulator, in Adults with Becker Muscular Dystrophy (Becker)

Muscular Dystrophy

March 2024

2024 MDA Annual Clinical and Scientific Conference

Characterization of Short- and Long-Term Proteomic Response to the Fast Skeletal Myosin Inhibitor, EDG-5506, in Becker Muscular Dystrophy (BMD)

Muscular Dystrophy

March 2024

2024 MDA Annual Clinical and Scientific Conference

Functional and Muscle Damage Biomarker Changes Following Treatment with EDG-5506, a Fast Myosin Modulator, in Adults with Becker Muscular Dystrophy

View Presentation